Products
- Anti-Obesity Compound Library
- GPCR/G Protein-Targeted Compounds
- Immunology/Inflammation-Targeted Compounds
- JAK/STAT-Targeted Compounds
- MAPK-Targeted Compounds
- Membrane Transporter/Ion Channel-Targeted Compounds
- Metabolism-Targeted Compounds
- NF-κB-Targeted Compounds
- Microbiology/Virology-Targeted Compounds
- Neuronal Signaling-Targeted Compounds
- PI3K/Akt/mTOR-Targeted Compounds
- Oxidation-reduction-Targeted Compounds
- Proteases/Proteasome-Targeted Compounds
- Stem Cells/Wnt-Targeted Compounds
- Tyrosine Kinase/Adaptors-Targeted Compounds
- Ubiquitin-Targeted Compounds
Online Inquiry
Furegrelate sodium
Cat. No.:
0225LY-0884
Appearance:
Solid
Purity:
≥99%
Identity:
Confirmed by NMR, HPLC, and LC-MS.
Size:
Add to basket
Product Overview
Description:
Furegrelate sodium is an orally active, selective thromboxane A2 (TXA2) synthase inhibitor that targets human platelet microsomes with an IC50 of 15 nM.
Synonym:
85666-17-7; Furegrelate (sodium); 5-(pyridin-3-ylmethyl)-1-benzofuran-2-carboxylate; 5-(3'-Pyridinylmethyl)benzofuran-2-carboxylate sodium; 2-Benzofurancarboxylic acid, 5-(3-pyridinylmethyl)-, sodium salt; Sodium 5-(3-pyridinylmethyl)-2-benzofurancarboxylate; Furegrelate sodium salt; MFCD00058448
CAS No.:
85666-17-7
Compound CID:
23663954
Formula:
C15H10NNaO3
Formula Weight:
275.23
Specification
Targets&IC50:
TXA2R: 15 nM
Stability:
3 years in powder form.
Storage:
Storage at -20°C.
Applications:
Furegrelate sodium can be used in cardiovascular research to examine the inhibition of thromboxane-mediated vasoconstriction.
Library Information
Target:
TXAS
Receptor:
TXA2R
Pathways:
Metabolism; DNA damage/DNA repair
Plate Number:
AOCL-12
Plate Location:
d3
Empty Location:
a1-h1; a12-h12
Container:
96-well plate
Formulation:
10mM DMSO
DMSO Max Solubility:
10 mg/mL; 36.33 mM
